Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Torticollis
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPEN-1
  • Sponsors Revance Therapeutics
  • Most Recent Events

    • 07 Jan 2019 According to a Revance Therapeutics media release, enrollment is progressing as planned in this study. The company expects to complete enrollment by early 2020.
    • 29 Jun 2018 New trial record
    • 21 Jun 2018 According to a Revance Therapeutics media release, this ASPEN Phase 3 clinical program consist of two studies (Randomized Trial (297124) and Open-Label Trial (290916) ) and expects to enrol 300 patients in this program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top